Tristel Share Discussion Threads

[zimbtrader] 17/6/2024 06:47

If the past is any indication, expect an announcement of the open day early to mid July with the open day at the end of July. A trading update would be released the morning of the open day.That's been the pattern over recent years, anyway.

[gopher] 10/6/2024 16:41

And now a new CEO, on paper a solid hire - they usually have an open day in the summer does anyone know when exactly?

[piedro] 06/6/2024 01:42

Tristel are hiring in Spain ...



- a sales representative and
- a financial administrator

[piedro] 31/5/2024 23:50

TRISTEL

28 May 2024
Navigating the Shadows – Understanding 6 Uncertainties with UV-C Technologies

[z1co] 23/5/2024 19:12

Trading update still a good few weeks away and in the absence of any news shares will keep sliding towards the £4.00 level.

[z1co] 18/5/2024 14:29

Share price still on the downward trend , far too many selling these on any small rise £4.10 to £4.20 before the next trading update in July.

[piedro] 18/5/2024 12:44

"... the second day of the 17th Congress of the DGKH."

[zimbtrader] 15/5/2024 21:05

I hope so.Just bought back in again. Was the second share I bought back in 2011 and, perhaps, I have an emotional attachment. Let's hope it remains a positive emotion! ;-)

[piedro] 15/5/2024 12:30

I also think that TSTL will be fine ... for the moment.

[james188] 14/5/2024 18:10

Ecolab is clearly a serious competitor. The HeiQ offerings have been much more patchy to date. No pricing information yet. I agree that this needs watching, but I think that TSTL will be fine.

[piedro] 14/5/2024 10:33

Sorry for the repeat but I think this need watching

Ecolab and HeiQ introduce synbiotic cleaning products at Interclean

[thanks to LiveWire Plus on the HEIQ bb]

[melton john] 22/4/2024 15:35

Cheers Piedro, that was before my time. 2016 when I first bought. I agree with your view.

[piedro] 22/4/2024 14:32

Here is the RNS ...

RNS Number : 2836Z
18 September 2009
Licensing agreement for the Americas ...
Licensing agreement with The Clorox Company of the United States
Tristel plc ('Tristel'), the specialist infection and contamination control company, announces that it has licensed its proprietary chlorine dioxide chemistry to The Clorox Company ('Clorox'), a leading manufacturer and marketer of consumer products, including its namesake bleach. ... ...

I always have considered it as a maneouvre by Clorox to block Tristel from the US

[melton john] 22/4/2024 07:14

A while since I owned TSTL Piedro but still on mmy watch list. I must have missed the Clorox deal you refer to. Do you have a link please.

[piedro] 22/4/2024 06:30

FYI ...

22 April 2024
HeiQ Synbio Secures Ecolab Contract Win
HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene technologies, is pleased to announce that its Life Sciences Business Unit has signed a significant distributor agreement with Ecolab Inc. (NYSE: ECL) to supply HeiQ Synbio Cleaners, a product from the Company's industrial biotechnology platform that uses natural synbiotic ingredients to achieve high efficacy cleaning. ...



- sort of reminds me of the Tristel/Clorox deal

[wad collector] 10/4/2024 19:56

Do I see an imminent 2 yr high?

[piedro] 09/4/2024 21:02

LOL

To much of a liability with BYOT and
they also have the MadiChem boys on board.

Much better to wait for them to go bankrupt
and pick up and choose the pieces.

AIMHO, BWDIK.

[loafofbread] 09/4/2024 19:18

I'm suggesting Tristel buys Byotrol.

[wad collector] 09/4/2024 18:58

He is encouraging Tristel holders to buy Byotrol. If you read his first posting. So read before you get rude.

[petewy] 09/4/2024 16:34

Hey knucklehead have you got the right stock

[wad collector] 09/4/2024 15:43

Err, why would anyone want to buy into such a failing company? I note your postings for months as the price fell to practically nothing ; you must have lost a lot.

[loafofbread] 07/4/2024 19:33

If he was happy to splash out up to £2M on this deal, I would think £4M for the lot would be an absolute steal!

23 March 2020
TRISTEL plc
("Tristel" or the "Company")

Know-How License and Product Supply Agreement with Byotrol plc ("Byotrol")

Tristel plc (AIM: TSTL), the manufacturer of infection prevention and contamination control products announces that it has entered into a know-how licence and commercial collaboration with Byotrol ("Agreement"). The Agreement relates to the joint development of a biocidal formulation and Byotrol's development of two additional biocidal products and formulations that will be supplied and licensed to Tristel.
Jointly developed formulation
This formulation will create a unique surface disinfectant product for hospitals by combining the two companies' core technologies.
The formulation combines Tristel's chlorine dioxide chemistry, which is sporicidal meaning that it has the highest level of disinfection efficacy, with ACTIZONE, a Solvay S.A. technology developed in collaboration with Byotrol and which enables a disinfectant to have long-lasting efficacy on a surface for an 8-hour period after first application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". These products will be unique worldwide in combining sporicidal efficacy with residual disinfection efficacy.
Additional biocidal products
In addition, Byotrol will licence two biocidal formulations to Tristel for incorporation in its surface disinfectants range which is branded Cache. Cache represents a novel approach to today's very relevant issues of hospital hygiene and environmental concern.
The Byotrol products and formulations give Tristel access to intermediate level disinfectants that are effective against bacteria, viruses and yeasts in accordance with the requirements of European Test Norms. The disinfectants will be for use in hospitals and will conform with the requirements of the European Biocidal Products Registration (BPR), and the United Kingdom equivalent that will come into force post Brexit. As this legislation is implemented throughout the United Kingdom and Europe during the coming years various active ingredients that are commonly incorporated in hospital grade disinfectants will be withdrawn from use. Tristel has previously incorporated some of these active ingredients in the intermediate level disinfectants that it presents to hospitals alongside its high-performance chlorine dioxide disinfectants. The Agreement will ensure that Tristel will continue to comply fully with the future regulatory environment that will govern the manufacture and sale of disinfectants for surface disinfection.
Commercial arrangements
Tristel will manufacture all the products deriving from the formulations, whilst Byotrol will supply the ACTIZONE material. Byotrol will receive payments from Tristel based upon volumes manufactured and product sales. Tristel will be responsible for branding and global sales and marketing through its thirteen subsidiaries and 35 international distributors. We expect sales of these new products to commence in the next financial year.
Commenting on the collaboration and current trading conditions, Paul Swinney, Chief Executive of Tristel, said: "Tristel and Byotrol are both specialist infection prevention companies, and in recent years we have forged a close working relationship. This collaboration holds great promise for both businesses. For Tristel it provides us a future-proofed intermediate grade disinfectant that we will incorporate into our hospital surface disinfectants product portfolio.
"The second key element of the arrangement is that we will combine a sporicidal high-performance disinfectant, which has an unrivalled kill time, with long-lasting disinfection activity that is proven to last for eight hours in accordance with PAS2424, a test developed with BSI and currently under detailed review by the EU for EN status. This combination of technologies creates a ground-breaking proposition. It is akin to clearing a crowd out of a stadium in 30 seconds and then keeping the doors closed to stop anyone re-entering. We must caution, however, that adoption of new infection prevention technology is often slow in healthcare, as both our companies know from first-hand experience.

[james188] 07/4/2024 16:04

I struggle to think of a worse move for TSTL to make than to acquire Byotrol. It has all the rights that it needs and has much more important things to concentrate on.

[loafofbread] 07/4/2024 15:53

Assume you guys know you could pick up Byotrol before it goes private for 1X sales.

Buying it for 1p a share £4.3M would boost your share price much more than the cash/share outlay if you apply your current 5 X revenue rating going forward.

You have just paid them over £300k to buy back a tiny bit of their IP which shows the value in Byotrol.

It would be a shame if your CEO personal friendship with DT got in the way of a great result for Tristel share holders.